Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Coherus Oncology, Inc. shareholders approved Election of Class III Directors: Dennis M. Lanfear and Mats L. Wahlström at the 2023-06-07 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-07
Exact text from the filing
Proposal 1. The Company’s stockholders elected by a majority of votes cast both of the Class III director nominees below, Dennis M. Lanfear and Mats L. Wahlström, to the Board to hold office until the 2026 annual meeting of stockholders or until their successors are elected. BROKER NOMINEE FOR WITHHELD NON- VOTES Dennis M. Lanfear 57,378,374 1,424,977 7,102,965 Mats L. Wahlström 42,646,152 16,157,199 7,102,965
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Coherus Oncology, Inc. shareholders approved Non-binding advisory resolution to approve the compensation of the Company's named executive officers (Say-on-Pay) at the 2023-06-07 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-07
Exact text from the filing
Proposal 3. The Company’s stockholders approved a non-binding, advisory resolution to approve the compensation of the Company’s named executive officers (a “Say-on-Pay” vote). BROKER FOR AGAINST ABSTAIN NON-VOTES 55,379,513 3,233,870 189,968 7,102,965
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Coherus Oncology, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-07 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-07
Exact text from the filing
Proposal 2. The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. BROKER FOR AGAINST ABSTAIN NON-VOTES 65,375,866 434,987 95,463 0
View on SEC.gov